4 registered trials, newest registry update first. Showing only trials linked to Bimagrumab.
| Trial | Compound | Phase | Status | Sponsor | Enrolled | Primary completion | Registry updated |
|---|---|---|---|---|---|---|---|
| Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese NCT05616013 | Bimagrumab | Phase 2 | Completed | Eli Lilly and Company | 507 | May 16, 2024 | Jul 8, 2026 |
| A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight NCT06643728 | Bimagrumab | Phase 2 | Active not recruiting | Eli Lilly and Company | 252 | Jan 16, 2026 | May 26, 2026 |
| A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes NCT06901349 | Bimagrumab | Phase 2 | Withdrawn | Eli Lilly and Company | – | Jun 10, 2025 | Sep 24, 2025 |
| Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients NCT01925209 | Bimagrumab | Phase 2 / Phase 3 | Completed | Novartis Pharmaceuticals | 251 | Jan 6, 2016 | Aug 11, 2017 |
Data: ClinicalTrials.gov, U.S. National Library of Medicine. Registered trials only. This table does not report results or recommend anything.
